Palvella Therapeutics (PVLA) Accounts Payables (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Accounts Payables data on file, last reported at $5.4 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 22.56% year-over-year to $5.4 million in Q1 2026; TTM through Mar 2026 was $5.4 million, a 22.56% increase from a year earlier, with the FY2025 full-year figure at $4.6 million, changed 0.2% from the prior year.
• Accounts Payables for Q1 2026 stood at $5.4 million, up from $4.6 million in the prior quarter.
• Over the last five years, Accounts Payables for PVLA reached as high as $7.6 million in Q2 2023 and fell as low as $801000.0 in Q3 2024.
• Historically, Accounts Payables has averaged $3.6 million across 5 years, with a median of $4.2 million in 2022.
• On a YoY basis, Accounts Payables climbed as much as 389.96% in 2024 and fell as far as 87.26% in 2024.
• Year by year, Accounts Payables stood at $4.2 million in 2022, then plunged by 77.47% to $936000.0 in 2023, then surged by 389.96% to $4.6 million in 2024, then increased by 0.2% to $4.6 million in 2025, then rose by 18.45% to $5.4 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $5.4 million in Q1 2026, $4.6 million in Q4 2025, and $3.5 million in Q3 2025.